Second-line drug treatment cost effective for chronic TB in Peru

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.365, 2002-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Second-line drug therapy for osteoarthritis

By Brandt Kenneth D

Clinical Medicine, Vol. 1, Iss. 2, 2001-03 ,pp. : 110-112

Royal College Of Physicians

Access to resources Recommend Favorite

Amfebutamone for second-line treatment only

Inpharma, Vol. 1, Iss. 1309, 2001-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Second-line pemetrexed, docetaxel similarly effective for NSCLC

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

By Holmes J.

PharmacoEconomics, Vol. 22, Iss. 9, 2004-01 ,pp. : 581-589

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom

By Lewis G Peake M Aultman R Gyldmark M Morlotti L Creeden J de la Orden M

The Journal of International Medical Research, Vol. 38, Iss. 1, 2010-01 ,pp. : 9-21

Field House Publishing

Access to resources Recommend Favorite